Top Page
Centrica
(LSE:CNA)
Centrica (CNA) vs. iShares MSCI United Kingdom ETF (EWC)
Centrica Business Overview & Revenue Model
Centrica Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 19.91B | 26.46B | 23.74B | 14.74B | 12.25B |
| Gross Profit | 4.09B | -1.70B | 9.75B | 1.41B | 3.52B |
| EBITDA | 2.42B | 7.08B | 410.00M | 721.00M | 488.00M |
| Net Income | 1.33B | 3.93B | -782.00M | 586.00M | 41.00M |
Balance Sheet | |||||
| Total Assets | 18.73B | 21.37B | 29.04B | 27.09B | 17.12B |
| Cash, Cash Equivalents and Short-Term Investments | 6.22B | 6.85B | 4.84B | 5.06B | 1.82B |
| Total Debt | 3.51B | 4.10B | 3.96B | 4.58B | 5.29B |
| Total Liabilities | 13.92B | 17.13B | 27.76B | 24.34B | 15.74B |
| Stockholders Equity | 4.42B | 3.88B | 1.02B | 2.37B | 957.00M |
Cash Flow | |||||
| Free Cash Flow | 733.00M | 2.42B | 943.00M | 1.19B | 778.00M |
| Operating Cash Flow | 1.15B | 2.75B | 1.31B | 1.61B | 1.27B |
| Investing Cash Flow | 493.00M | 115.00M | -566.00M | 2.26B | -354.00M |
| Financing Cash Flow | -1.55B | -1.41B | -917.00M | -938.00M | -280.00M |
Centrica Technical Analysis
Centrica Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £20.28B | 17.09 | 12.29% | 2.30% | -3.11% | -31.10% | |
72 Outperform | £7.40B | 6.04 | 32.10% | 3.92% | -24.74% | -63.34% | |
71 Outperform | £51.22B | 17.03 | 8.35% | 5.91% | -7.42% | 5.84% | |
67 Neutral | $16.46B | 16.85 | 4.47% | 3.80% | 4.76% | 6.06% | |
63 Neutral | £8.02B | 34.46 | 12.73% | 5.48% | 3.78% | 50.18% | |
62 Neutral | £7.56B | 28.54 | 13.05% | 6.24% | 10.04% | ― | |
57 Neutral | £2.31B | ― | -4.44% | 6.01% | 15.42% | -406.43% |
Centrica Corporate Events
Centrica plc has announced the purchase of 2,491,697 of its own ordinary shares at a price of 154.0300 pence per share, as part of the first tranche of its 2025 buyback programme. This move, executed through Goldman Sachs International, is part of a broader strategy to manage the company’s capital structure and return value to shareholders, reflecting Centrica’s ongoing commitment to optimizing shareholder returns.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £1.85 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,691,824 of its own ordinary shares at a price of 154.6100 pence per share, as part of its 2025 buyback program. This transaction, facilitated by Goldman Sachs International, is part of an ongoing effort to manage the company’s capital structure, with a total of 53,897,361 shares purchased since June 2025, reflecting a strategic move to enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,324,123 of its own ordinary shares at a price of 155.3600 pence per share, as part of the first tranche of its 2025 buyback programme. This transaction, conducted through Goldman Sachs International, is part of a broader strategy to manage the company’s capital structure and return value to shareholders. Following this purchase, Centrica holds 482,475,396 shares in treasury, with a total of 4,853,631,818 shares in issue. This move is likely to impact Centrica’s market positioning by potentially increasing shareholder value and optimizing its financial operations.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 1,978,581 ordinary shares on 14 July 2025, as part of its extended 2025 buyback program. The shares, bought at an average price of 155.6600 pence each, will be held as treasury shares. This move is part of a broader strategy to manage share capital and enhance shareholder value, having already acquired over 48 million shares since June 2025. The transaction underscores Centrica’s commitment to its buyback program, potentially impacting its market positioning and shareholder returns.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,765,135 of its own ordinary shares at a price of 154.6700 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of the first tranche of the programme’s extension, which was initially announced in February 2025. The shares will be held as treasury shares, contributing to a total of 478,172,692 treasury shares held by Centrica. This move is part of Centrica’s strategic financial management to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the granting of options to employees under its Sharesave Scheme, including executive directors Christopher O’Shea and Russell O’Brien. Additionally, shares were acquired by these directors under the Share Incentive Plan, indicating a strategic move to align management interests with company performance, potentially impacting stakeholder confidence positively.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £175.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has executed a share buyback transaction, purchasing 1,418,627 of its ordinary shares at a price of 155.6800 pence per share through Goldman Sachs International. This transaction is part of the first tranche of the company’s 2025 buyback program, which began in February 2025. Since mid-June 2025, Centrica has acquired over 45 million shares, reflecting a strategic move to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,549,246 of its own ordinary shares at a price of 157.8300 pence per share as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of an ongoing effort to manage the company’s share capital and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 2,240,728 of its own ordinary shares at a price of 156.9800 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of a larger effort that has seen the company acquire over 42 million shares since June 2025. The move is expected to strengthen Centrica’s financial position by consolidating its share capital, potentially increasing shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has appointed Alessandra Pasini as a Non-Executive Director, enhancing its board with her extensive experience in energy infrastructure and sustainability. Pasini’s background in renewable energy and strategic leadership is expected to bolster Centrica’s efforts in advancing its energy transition initiatives.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 3,466,214 of its own ordinary shares at a price of 158.9400 pence per share, as part of its 2025 buyback programme. This transaction, conducted through Goldman Sachs International, is part of an ongoing effort to manage its share capital, with a total of 39,929,097 shares purchased since June 2025. The move is expected to impact the company’s financial structure by increasing the number of treasury shares to 471,428,697, while maintaining 4,864,678,517 shares in issue.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,335,454 of its own ordinary shares at a price of 159.1000 pence per share, as part of its 2025 buyback programme. This move is part of a larger strategy to manage its capital structure and enhance shareholder value, reflecting the company’s ongoing commitment to returning capital to shareholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 2,284,753 of its own ordinary shares at a price of 159.6000 pence per share, as part of its 2025 buyback programme. This transaction, conducted through Goldman Sachs International, is part of a broader strategy to manage its capital structure, potentially impacting shareholder value and market perception.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 2,954,780 of its own ordinary shares on July 1, 2025, as part of its 2025 buyback programme. The shares were acquired at an average price of 161.2100 pence each and will be held as treasury shares. This transaction is part of the first tranche of the buyback extension announced earlier in the year. Since mid-June, Centrica has repurchased over 30 million shares, reflecting its strategy to enhance shareholder value and optimize its capital structure.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced its total voting rights as of June 30, 2025, with an issued capital comprising over 5.3 billion ordinary shares. Of these, approximately 4.88 billion shares carry voting rights, which shareholders can use to determine their notification obligations under the Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 4,431,259 of its own ordinary shares at a price of 161.0600 pence per share, as part of its 2025 buyback programme. This transaction, facilitated by Goldman Sachs International, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value. Following this purchase, Centrica holds 459,876,257 shares in treasury, reflecting its ongoing commitment to its buyback initiative.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has released its report on payments made to governments for the year ending December 31, 2024, in compliance with the Disclosure and Transparency Rules. The report, which details payments made to the UK, Netherlands, and Norway, will be available for inspection from the National Storage Mechanism and on Centrica’s website. The report highlights a total payment of GBP 364,750, with the majority being production entitlements and taxes paid in the United Kingdom. This disclosure reflects Centrica’s commitment to transparency and regulatory compliance, potentially affecting its reputation and stakeholder relations.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 3,242,084 of its own ordinary shares at a price of 164.0400 pence each, through Goldman Sachs International, as part of its 2025 buyback programme. This transaction is part of the first tranche of the programme’s extension, which was initially announced in February 2025. The purchased shares will be held as treasury shares, contributing to a total of 455,444,998 treasury shares held by the company. The buyback programme is a strategic move to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of over 3 million of its own ordinary shares as part of its 2025 buyback program, executed through Goldman Sachs International. This move is part of a broader strategy to manage its capital structure and enhance shareholder value, reflecting the company’s ongoing commitment to returning capital to shareholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the vesting of awards under its Long Term Incentive Plan, initially granted in 2022, which vested in full on June 23, 2025. Following the vesting, shares were sold to cover statutory withholding liabilities, with the remaining shares subject to a mandatory two-year holding period. This transaction reflects Centrica’s ongoing commitment to aligning executive incentives with company performance, potentially impacting shareholder value and executive retention strategies.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,640,045 of its own ordinary shares at a price of 165.3400 pence per share, as part of its 2025 buyback programme. This move, executed through Goldman Sachs International, is part of a broader strategy to manage its share capital, potentially enhancing shareholder value and signaling confidence in the company’s financial health.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced that Philippe Boisseau, a Non-Executive Director, acquired ordinary shares of the company as part of a Share Purchase Agreement. This transaction, conducted on the London Stock Exchange, reflects ongoing engagement and investment by the company’s leadership, potentially influencing investor confidence and market perception.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 2,332,205 of its own ordinary shares at a price of 166.2200 pence per share, as part of the first tranche of its 2025 buyback programme. This move reflects Centrica’s ongoing efforts to manage its capital structure and return value to shareholders, with the purchased shares being held as treasury shares. Since mid-June 2025, the company has acquired over 15 million shares, indicating a significant commitment to its buyback strategy, which could positively impact shareholder value and market perception.
The most recent analyst rating on (GB:CNA) stock is a Hold with a £160.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 2,494,394 of its own ordinary shares at a price of 167.8700 pence per share, as part of an extension to its 2025 buyback programme. This transaction, executed through Goldman Sachs International, reflects Centrica’s strategic effort to manage its share capital and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has executed a share buyback program, purchasing 1,870,684 of its own ordinary shares at a price of 167.0000 pence per share through Goldman Sachs International. This transaction is part of the first tranche of the company’s 2025 buyback programme, which began in February 2025. As a result of this purchase, Centrica now holds 446,378,337 shares in treasury, with a total of 4,889,728,877 shares in issue. This move is likely to impact the company’s market positioning by potentially increasing shareholder value and optimizing capital structure.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has executed a share buyback program, purchasing over 2 million of its own shares at an average price of 167.4600 pence per share, as part of its 2025 buyback initiative. This move, facilitated through Goldman Sachs International, is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has executed a significant share buyback, purchasing 3,363,123 ordinary shares at a price of 167.1500 pence per share, as part of its 2025 buyback programme. This move is expected to enhance shareholder value by reducing the number of shares in circulation, potentially increasing earnings per share and strengthening the company’s market position.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,624,762 of its own ordinary shares at a price of 167.1100 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, is part of a broader strategy to manage the company’s capital structure and return value to shareholders, reflecting Centrica’s ongoing commitment to enhancing shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 1,713,670 of its ordinary shares at a price of 167.8400 pence per share, as part of its 2025 buyback programme. This transaction, executed through Goldman Sachs International, reflects Centrica’s ongoing efforts to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has completed a significant phase of its share buyback program, purchasing nearly 2.9 million shares to be held as treasury shares. This action is part of an extended buyback initiative aimed at enhancing shareholder value, with the next phase involving Goldman Sachs International set to commence, targeting a maximum of £250 million in share repurchases.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 2,487,940 of its own ordinary shares at a price of 164.35 pence per share, as part of its ongoing 2024-25 buyback program. This move is part of a broader strategy to manage its capital structure and return value to shareholders, with the company having acquired over 172 million shares since March 2025.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the acquisition of ordinary shares under its Share Incentive Plan by its executive directors, Christopher O’Shea and Russell O’Brien. The transactions, conducted on June 11, 2025, involved the purchase of Partnership and Matching Shares, highlighting the company’s ongoing commitment to aligning management interests with shareholder value. This move may strengthen Centrica’s market position by ensuring executive alignment with company performance, potentially impacting stakeholder confidence positively.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the cancellation of 82 million ordinary shares held in treasury, aligning with its policy to keep treasury shares below 10% of total issued share capital. This cancellation reduces the treasury shares to 8.09% of the company’s total issued share capital, impacting the company’s share structure and potentially influencing shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,571,065 of its own ordinary shares at 163.99 pence each, as part of its extended 2024-25 buyback programme. This transaction, executed through Merrill Lynch International, brings the total shares purchased since March 2025 to 170,087,788, costing over £261 million. The shares will be held as treasury shares, increasing Centrica’s treasury stock to 513,792,560 shares, which may impact the company’s share value and investor perception.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 4,202,141 of its own ordinary shares at a price of 163.28 pence per share, as part of its extended 2024-25 buyback programme. This transaction, executed through Merrill Lynch International, is part of a broader strategy to manage the company’s capital structure and enhance shareholder value, with Centrica now holding 511,221,495 ordinary shares in treasury.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 7,535,656 of its own ordinary shares at a price of 160.72 pence per share, as part of its extended 2024-25 buyback program. This transaction, executed through Merrill Lynch International, increases the total number of shares held in treasury to 507,727,029, reflecting Centrica’s ongoing efforts to manage its capital structure and enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has executed a share buyback transaction, purchasing over 7.3 million of its own shares at an average price of 161.04 pence per share. This move is part of an ongoing buyback program aimed at optimizing the company’s capital structure and potentially enhancing shareholder value by reducing the number of shares in circulation.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced that its ordinary shares were acquired through the reinvestment of its 2024 final dividend under the company’s Share Incentive Plan. This transaction involved key executives, including Christopher O’Shea and Russell O’Brien, acquiring shares on the London Stock Exchange, highlighting the company’s ongoing commitment to aligning management interests with shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 6,650,293 of its own ordinary shares at a price of 161.48 pence per share, as part of its extended 2024-25 buyback programme. This transaction, conducted through Merrill Lynch International, increases the total shares held in treasury to 493,879,655, reflecting Centrica’s ongoing strategy to manage its capital structure and enhance shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of over 3.2 million ordinary shares as part of its extended 2024-25 buyback program. This strategic move, executed through Merrill Lynch International, reflects Centrica’s ongoing efforts to manage its capital structure and enhance shareholder value. The company now holds a significant number of shares in treasury, which could impact its market positioning and shareholder returns.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £175.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,628,754 of its own ordinary shares at a price of 162.88 pence per share, as part of its extended 2024-25 buyback programme. This move is in line with the company’s strategy to manage its capital structure and enhance shareholder value, reflecting a significant investment in its own equity, which could impact its market positioning and shareholder confidence.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 3,434,600 of its own ordinary shares at a price of 157.85 pence per share, executed through Merrill Lynch International. This transaction is part of the company’s ongoing 2024-25 share buyback program, which was extended in December 2024. Since March 2025, Centrica has acquired over 135 million shares, reflecting a significant investment in its own stock, which could indicate confidence in its market position and future prospects.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced its total voting rights as of May 31, 2025, with 4,937,965,976 shares carrying voting rights. This information is crucial for shareholders and others with notification obligations to determine their interest in the company under the Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,947,146 of its own ordinary shares at an average price of 158.53 pence per share, as part of its extended 2024-25 buyback program. This move, executed through Merrill Lynch International, reflects Centrica’s ongoing strategy to manage its capital structure and return value to shareholders, with a total of 132,414,218 shares repurchased since March 2025, costing over £200 million.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced that its Non-Executive Director, Philippe Boisseau, has acquired ordinary shares in the company as part of a Share Purchase Agreement. This transaction, conducted on the London Stock Exchange, reflects ongoing director-level investments in the company, potentially signaling confidence in Centrica’s market position and future prospects.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 4,520,656 of its own ordinary shares at a price of 157.30 pence per share, as part of its extended 2024-25 buyback programme. This move, executed through Merrill Lynch International, is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value, reflecting Centrica’s commitment to optimizing its financial operations and market positioning.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 1,580,561 of its own ordinary shares at a price of 156.16 pence per share, as part of its extended 2024-25 buyback programme. This move is part of a larger strategy to manage its capital structure and enhance shareholder value, with a significant number of shares now held in treasury, reflecting the company’s ongoing commitment to its financial strategies.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of over 2 million of its own ordinary shares at an average price of 156.17 pence per share, as part of its extended 2024-25 buyback programme. This transaction, executed through Merrill Lynch International, reflects Centrica’s ongoing efforts to manage its capital structure and return value to shareholders, holding a total of 471 million shares in treasury following this purchase.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the publication of its updated Base Prospectus for its Euro Medium Term Note Programme, which has been approved by the Financial Conduct Authority. This update, involving a substantial U.S.$10 billion program, is significant for Centrica’s financial strategy and could impact its market positioning by enhancing its ability to raise capital efficiently.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the cancellation of 75 million of its ordinary shares previously held in treasury, as part of its policy to keep treasury shares below 10% of its total issued share capital. This move leaves the company with 469 million treasury shares, representing 8.66% of its total issued share capital, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 4,314,801 of its own ordinary shares at a price of 157.58 pence per share as part of its extended 2024-25 buyback program. This transaction, executed through Merrill Lynch International, contributes to Centrica’s strategy of managing its capital structure and returning value to shareholders, with a total of 121,282,673 shares purchased since March 2025. The company now holds 544,009,693 shares in treasury, impacting its share issuance and potentially influencing market perceptions and shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has executed a share buyback transaction, purchasing 3,434,808 of its own ordinary shares at a price of 158.00 pence per share through Merrill Lynch International. This purchase is part of Centrica’s extended 2024-25 buyback program, which has seen the company acquire over 116 million shares since March 2025, reflecting its strategic focus on returning value to shareholders and optimizing its capital structure.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 3,973,444 of its own ordinary shares at a price of 157.97 pence each, as part of its extended 2024-25 buyback program. This transaction, conducted through Merrill Lynch International, increases Centrica’s treasury shares to 536,260,084, impacting its overall share capital structure and potentially enhancing shareholder value.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 4,406,647 of its own ordinary shares at a price of 155.21 pence per share, as part of its ongoing 2024-25 buyback program. This transaction, executed through Merrill Lynch International, is part of a broader strategy to manage the company’s capital structure and return value to shareholders, with a total of 109,559,620 shares purchased since March 2025 at a cost of over £164 million. The buyback program reflects Centrica’s commitment to enhancing shareholder value and optimizing its financial operations.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 4,593,197 of its own ordinary shares at a price of 151.06 pence per share, as part of its extended 2024-25 buyback program. This move is in line with the company’s strategy to manage its capital structure and return value to shareholders, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica has announced that its subsidiary, Spirit Energy, will sell a 46.25% stake in the Cygnus gas field to Ithaca Energy for approximately £215 million. This move aligns with Centrica’s strategy to reduce its exposure to gas production and focus on the Morecambe Net Zero carbon storage project, enhancing shareholder value and supporting the energy transition.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 4,800,835 of its own ordinary shares at a price of 148.87 pence per share, as part of its extended 2024-25 buyback programme. This move, conducted through Merrill Lynch International, is part of Centrica’s strategy to manage its capital structure and return value to shareholders, reflecting its ongoing commitment to financial optimization.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 4,796,475 of its own ordinary shares at a price of 148.46 pence per share, as part of its extended 2024-25 buyback programme. This move is part of Centrica’s strategy to manage its capital structure and return value to shareholders, potentially impacting its market positioning by reducing the number of shares in circulation and increasing earnings per share.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,477,748 of its own ordinary shares at a price of 146.11 pence per share, as part of its ongoing 2024-25 share buyback program. This move, executed through Merrill Lynch International, is part of a broader strategy to manage its capital structure and return value to shareholders, with significant shares being held in treasury. The buyback program reflects Centrica’s commitment to enhancing shareholder value and optimizing its financial operations.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the purchase of 2,559,712 of its own ordinary shares at an average price of 147.54 pence per share, as part of its extended 2024-25 buyback programme. The shares will be held in treasury, contributing to a total of 511,211,738 treasury shares. This move is part of Centrica’s strategy to manage its capital structure and return value to shareholders, potentially impacting its stock market performance and investor relations.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc announced the acquisition of shares under its Share Incentive Plan by executive directors Christopher O’Shea and Russell O’Brien. The transactions, which involved acquiring both Partnership and Matching Shares, were conducted on the London Stock Exchange and outside a trading venue. This move reflects Centrica’s ongoing efforts to align management interests with shareholder value, potentially impacting the company’s market positioning and stakeholder relations.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 2,436,011 of its own ordinary shares at a price of 148.16 pence per share, as part of its extended 2024-25 buyback programme. This move is in line with the company’s strategy to manage its capital structure and enhance shareholder value, reflecting its commitment to returning capital to shareholders.
The most recent analyst rating on (GB:CNA) stock is a Buy with a £150.00 price target. To see the full list of analyst forecasts on Centrica stock, see the GB:CNA Stock Forecast page.
Centrica plc has announced the purchase of 6,469,621 of its own ordinary shares at a price of 148.53 pence per share, which will be held as treasury shares. This transaction is part of the company’s extended 2024-25 buyback program, reflecting its ongoing strategy to manage its capital structure and potentially enhance shareholder value.
Centrica plc has announced the purchase of 4,933,619 of its own ordinary shares, priced at 147.72 pence each, as part of its ongoing 2024-25 buyback programme. This transaction, conducted through Merrill Lynch International, reflects Centrica’s strategic financial management aimed at consolidating its market position and potentially enhancing shareholder value.
Centrica plc held its 2025 Annual General Meeting where all proposed resolutions were passed, including the approval of the company’s annual report, directors’ remuneration policy, and a final cash dividend. The board acknowledged shareholder support but noted the significant opposition to the Directors’ Remuneration Report, indicating ongoing engagement with shareholders to address concerns. The meeting’s outcomes reflect Centrica’s commitment to maintaining transparency and shareholder engagement, which could influence its corporate governance and stakeholder relations.
Centrica plc has announced an extension of its share buyback program, adding £500 million to the initiative, bringing the total to £2.0 billion. The first £250 million tranche will be managed by Goldman Sachs International, with the aim of reducing the company’s capital. This move is expected to impact Centrica’s market positioning by potentially increasing shareholder value and optimizing capital structure.
Centrica plc has announced the purchase of 4,856,598 of its own ordinary shares at a price of 159.03 pence per share, as part of its extended 2024-25 buyback programme. This move, executed through Merrill Lynch International, reflects Centrica’s ongoing strategy to manage its capital structure and return value to shareholders, potentially enhancing its market position and shareholder confidence.
Centrica plc has executed a share buyback transaction, purchasing over 4.7 million of its ordinary shares at an average price of 158.95 pence per share. This move is part of its extended 2024-25 buyback program, indicating a strategic effort to consolidate its share capital and potentially enhance shareholder value. The company now holds approximately 490 million shares in treasury, reflecting its ongoing commitment to managing its capital structure efficiently.
Centrica plc has executed a share buyback transaction, purchasing over 4.4 million of its own ordinary shares at an average price of 157.87 pence per share. This move is part of an extended buyback program initially announced in December 2024, aimed at enhancing shareholder value. As a result of this transaction, Centrica now holds over 485 million shares in treasury, reflecting its strategic focus on optimizing its capital structure and potentially improving earnings per share.
Centrica plc announced the purchase of 4,338,792 ordinary shares at a price of 158.13 pence per share, as part of its extended 2024-25 buyback program. This transaction, conducted through Merrill Lynch International, is part of a broader strategy to manage its capital structure and enhance shareholder value, reflecting the company’s commitment to optimizing its financial operations and market positioning.
Centrica plc announced the total voting rights as of April 30, 2025, with an issued capital comprising over 5 billion ordinary shares. Of these, more than 5 billion shares have voting rights, which is crucial for shareholders to determine their interest in the company under the Disclosure Guidance and Transparency Rules.
Centrica plc has announced the purchase of 1,111,279 of its own ordinary shares at a price of 159.71 pence per share, as part of its extended 2024-25 buyback programme. This move is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value, reflecting Centrica’s ongoing commitment to its financial strategies and market positioning.
Centrica plc announced that Philippe Boisseau, a Non-Executive Director, acquired 1,230 ordinary shares of the company at a price of £1.582650 per share, totaling £1,946.66. This transaction, conducted on the London Stock Exchange, is part of a Share Purchase Agreement established with the company, highlighting ongoing director engagement and investment in Centrica.
Centrica plc announced the purchase of 1,043,938 of its own ordinary shares at a price of 157.71 pence per share, as part of its 2024-25 buyback programme. This move is in line with the company’s strategy to manage its capital structure and return value to shareholders, potentially impacting its market positioning by reducing the number of shares in circulation and increasing the value of remaining shares.
Centrica plc has announced the purchase of 96,066 of its own ordinary shares, at a price of 155.57 pence per share, as part of its ongoing 2024-25 buyback programme. This transaction, executed through Merrill Lynch International, reflects Centrica’s strategic focus on managing its capital structure and returning value to shareholders. Following this purchase, Centrica holds a significant number of shares in treasury, indicating a robust approach to enhancing shareholder value and potentially impacting its market positioning.
Centrica plc announced a change in major holdings due to an acquisition or disposal of financial instruments by Bank of America Corporation. This adjustment in holdings reflects a decrease in the percentage of voting rights held by Bank of America, which could impact Centrica’s shareholder dynamics and influence within the company.
Centrica plc has announced the purchase of 97,721 of its own ordinary shares at a price of 153.39 pence per share, as part of its ongoing share buyback program. This move is part of the company’s strategy to manage its capital structure and return value to shareholders, reflecting its commitment to financial discipline and enhancing shareholder returns.
Centrica plc has announced the purchase of 2,068,752 of its own ordinary shares at a price of 152.82 pence per share, as part of its ongoing 2024-25 buyback programme. This transaction, conducted through Merrill Lynch International, is part of Centrica’s strategy to manage its capital structure and return value to shareholders, reflecting the company’s commitment to optimizing shareholder returns.
Centrica plc announced the purchase of 3,914,749 of its own ordinary shares at a price of 151.79 pence per share, as part of its extended 2024-25 buyback program. This transaction, executed through Merrill Lynch International, reflects Centrica’s ongoing strategy to manage its capital structure and enhance shareholder value, with a total of 48,166,613 shares purchased since March 2025.
Centrica plc has announced the purchase of 100,000 of its own ordinary shares at a price of 149.51 pence per share, as part of its ongoing 2024-25 buyback programme. This transaction is part of a broader strategy to manage its capital structure and potentially enhance shareholder value, reflecting Centrica’s commitment to returning capital to shareholders.